Potential SARS-CoV-2 antiviral to be tested in human lung cells
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
List view / Grid view
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
Dr Sotirios Karathanasis discusses the history of cannabis as a treatment and delves into the process of turning plant-based medicines into clinically proven drugs.
Scientists have created an antiviral therapy using lipid nanoparticles that deliver siRNA to the lungs to treat COVID-19 in mice.
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
Researchers from the University of Minnesota have developed a 3D spherical microfluidic device. Here, Dr Ruitao Su explains how the new device can be used in drug discovery and development.
A new pre-clinical mouse model could enable the study of HIV infection and the testing of cell therapies against the virus.
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
A new vaccine has shown promise at protecting monkeys and mice from COVID-19, its variants and other coronaviruses.
Researchers have found that a metabolite of remdesivir potentially targets a SARS-CoV-2 protein involved in suppressing the host cell's defence response.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
According to new research, the biochip market will grow as a result of the rising demand for personalised medicine.
Scientists have developed a 3D lung-on-a-chip model of the distal lung and alveolar structures, enabling the study of COVID-19.